title: Does maximizing programmed cell death necessarily yield an optimum clinical advantage?
abstract: Generally it has been believed that a maximum therapeutic induction of programmed cell death in cancer cells is universally desirable. As a corollary, the presence of Bcl-2, a major anti-programmed cell death protein, is considered an unfavorable prognostic sign. The latter is not and the former may not be universally true.
authors.affiliation: Department of Pathology, University of Illinois Medical School at Chicago and the West Side V.A. Hospital, USA.
authors.forename: D
authors.initials: D
authors.lastname: Ou
authors.forename: K M
authors.initials: KM
authors.lastname: Anderson
authors.forename: W
authors.initials: W
authors.lastname: Leslie
authors.forename: P
authors.initials: P
authors.lastname: Bonomi
authors.forename: J E
authors.initials: JE
authors.lastname: Harris
mesh_terms: D000818:Animals; D017209:Apoptosis; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis / Q000502:physiology
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2